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Abstract: SU1498, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), has activity 
against retinal neovascular diseases. To determine if this drug might have clinical utility against retinoblastoma, we evalu-
ated the effects of SU1498, as well as the expression of VEGFR-2, in a transgenic animal model of retinoblastoma. Opti-
cal coherence tomography (OCT) was evaluated as a technology to measure retinal tumors in vivo, in response to treat-
ment. Immunofluorescence analysis was performed to evaluate the distribution and expression of VEGFR-2 in enucleated 
eyes from LHTag transgenic mice and controls at 4, 8, 12, and 16 weeks of age. VEGFR-2 and phosphorylated 
(p)VEGFR-2 levels were quantitated by Western blot. OCT was used to pair 10-week-old animals based on tumor volume 
(n=10), and these animals were treated with 6 periocular injections of SU1498 (50mg/kg, given twice weekly) or vehicle 
for 3 weeks. Tumor burden was determined by histology and in vivo imaging by OCT. VEGFR-2 and pVEGFR-2 expres-
sion levels were upregulated during tumorigenesis. However, SU1498 did not significantly reduce tumor burden com-
pared to vehicle (p=0.29). OCT imaging of one matched pair demonstrated equivalent, linear tumor growth despite treat-
ment with SU1498. Retinal tumors can be followed non-invasively and quantitatively measured with OCT. VEGFR-2 is 
strongly upregulated during tumorigenesis in transgenic retinoblastoma; however, SU1498 does not decrease tumor vol-
ume in transgenic murine RB at the studied dose and route of administration. 
INTRODUCTION 
  Retinoblastoma generates a robust angiogenic response 
important for its growth and survival [1-5]. Investigating the 
mechanisms of this response is a major goal for developing 
new adjuvant therapies for retinoblastoma. 
  Using the LHTag transgenic mouse model of retinoblas-
toma, we have shown that tumor burden is significantly de-
creased by two independent, anti-angiogenic treatments, 
combretastatin A-4 [6] and anecortave acetate [7]. Evaluat-
ing novel anti-angiogenic agents with different mechanisms 
of action is a promising strategy, as multiple drugs may 
eventually be combined for a more robust effect. 
  VEGFR-2 (also known as KDR or FLK-1) is a high af-
finity tyrosine kinase receptor for VEGF, known to be very 
important in mediating normal and pathologic angiogenic 
responses, especially in cancer [2, 8-14]. Recently, anti-
angiogenic drugs which inhibit VEGFR have been devel-
oped which have shown promise in treating a variety of can-
cers [15-21]. One promising drug is SU1498, a tyrosine 
kinase inhibitor specific for VEGFR-2 [22]. Saishin et al. 
previously showed that SU1498 blocks retinal vascular leak-
age mediated by VEGF in a murine model [23]. With these 
novel therapies, it is important to confirm the tumor, or its 
microenvironment, express the molecules targeted by the 
therapy. Stitt et al. demonstrated previously that human reti-
noblastoma expresses VEGFR-2 [2]. 
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 The  LHTag mouse model of retinoblastoma is a trans-
genic mouse that expresses the SV40 Large T antigen. This 
protein sequesters p53 and pRB resulting in heritable, bilat-
eral, multifocal retinal tumors that initiate in the inner nu-
clear layer and are histologically similar to human retino-
blastoma [24-29]. Although, the mechanism of tumor initia-
tion between human RB and LHTag retinal tumors is dif-
ferent, this model is one of the best preclinical models to 
evaluate novel anti-retinoblastoma therapies. Herein, we 
tested the hypothesis that VEGFR-2 is upregulated and 
phosphorylated in transgenic murine RB and that the 
VEGFR-2 inhibitor SU1498 decreases tumor burden. OCT 
imaging was used to evaluate the tumor response to therapy 
in vivo. 
MATERIALS AND METHODOLOGY 
Animals 
  The study protocol was approved by the University of 
Miami, School of Medicine Animal Care and Use Review 
Board, Miami, FL. All experiments in this study were con-
ducted in accordance with the Association for Research in 
Vision and Ophthalmology guidelines for the use of animals 
in ophthalmologic and vision research. Transgenic mice 
positive for the LHTag construct have been previously de-
scribed, and were identified through polymerase chain reac-
tion analysis of tail DNA [24-29]. 
Immunofluorescence Analysis 
  Transgenic and background control mice were sacrificed 
with CO2 gas at 4, 8, 10-12, or 16 weeks (n=4 per group). 
Eyes were enucleated, snap frozen in optimal cutting tem-
perature compound (Tissue Tek), and sectioned serially (5 Lack of Effect of SU1498  The Open Ophthalmology Journal, 2008, Volume 2    63 
microns). For immunofluorescence, slides were fixed with 
cold methanol 15 minutes at -20
oC. Blocking solution (phos-
phate buffered saline (PBS) with 5% bovine serum albumin, 
and 1% Triton-X 100) was added to the slides for 1 hour at 
room temperature and drained off. VEGFR-2 was detected 
with a rat monoclonal antibody (clone 4H3B6H9, Chemicon 
International, Temecula, CA) and Alexa Fluor 488-
conjugated secondary antibody (Invitrogen). As a control, 
the primary antibody was omitted. DAPI (Invitrogen) was 
used as a counterstain. Slides were coverslipped with Anti-
fade mounting media (Biomeda, Foster City, CA). 
  Twelve to 16 sections per eye were viewed with an 
Olympus Bx51 fluorescent microscope and images were 
digitally acquired. Exposure times for VEGFR-2 im-
munofluorescence were standardized within each experi-
ment. 
Histologic Tumor Burden Analysis 
  Tumor burden was determined by standard hematoxylin 
and eosin-(H&E) as previously described [30]. Four of every 
6 frozen sections of the eye were fixed in 4% paraformalde-
hyde and stained with H&E. All stained sections were evalu-
ated for the largest tumor area at a magnification of 40X. 
Digital photographs were acquired and the tumor area was 
calculated and normalized to the area of the globe [30]. 
Western Blot 
  Retinas and retinal tumors (n=8 per group) from 4, 8, and 
16 week-old LHTag mice and background controls were 
removed under a dissecting microscope using a #10 blade 
scalpel and iris spatula (FST Instruments). Non-retinal struc-
tures were removed with jewelers’ forceps. Retinas and tu-
mors were pooled and homogenized with cold extraction 
buffer (125 mM TrisCl pH 7.0, 100 mM NaCl and 1% So-
dium dodecyl sulphate (SDS)). Proteins were quantitated 
using the Bradford method. Equal microgram quantities of 
protein were suspended in Laemmli buffer and fractionated 
with SDS-PAGE on 4-20% precast gels (Invitrogen). Re-
combinant human VEGFR-2-Fc chimera (R&D Systems) 
was used as a positive control for VEGFR-2 and pVEGFR-2 
proteins. Proteins were electroblotted onto a polyvinylidene 
fluoride (PVDF) membrane. Membranes were blocked with 
5% nonfat milk and incubated with VEGFR-2 primary anti-
body (FLK-1 (C-1158), Santa Cruz) or pVEGFR2 primary 
antibody (PhosphoDetect Anti-VEGFR2 (pTyr1214), Cal-
biochem) and a secondary antibody conjugated to horserad-
ish peroxidase. Blots were developed using ECL chemilumi-
nescence. Blots were stripped and re-probed for -actin 
(clone C4, Santa Cruz) as a loading control. 
OCT Analysis 
  A spectral-domain optical coherence tomography (OCT) 
system for noninvasive, in vivo, high resolution imaging of 
rodent retina was used as previously described [31]. The 
configuration of the OCT system used in this study is similar 
to the previous study except that the depth resolution was 
improved to ~3 m in tissue. The right eyes of 10 LHTag 
mice were imaged in vivo, and the mice were paired accord-
ing to greatest cross-sectional tumor width: small (<1/3 mm), 
medium (1/3 mm to <3/4 mm), medium-large (3/4mm to 
<1mm), large (1mm to <1.5mm), and very large (1.5mm).  
 
For one select pair (animal numbers II8 and MM8), the tu-
mor location was registered and volume was extracted once a 
week for 3 weeks (time 0, week 1, week 2, and week 3 post-
injection #1). A semiautomatic segmentation tool for seg-
menting the tumor boundaries in each OCT cross-sectional 
image was used. The tumor volume was then calculated 
automatically using the segmented boundaries. 
SU1498 Experiments 
  Spectral OCT was used to pair 10-week-old LHTag 
mice based on tumor volume (n=10). Paired animals were 
treated with 6 periocular injections (given in a 10l volume 
twice weekly for 3 weeks) of either SU1498 (50mg/kg, LC 
Labs, n=5) or DMSO vehicle (n=5). Mice were sacrificed 4 
days after the final injection. Tumor burden was determined 
by H&E histology and weekly, in vivo imaging by OCT. The 
dose of SU1498 was based on studies by Saishin et al. [23], 
which demonstrated prevention of retinal leakage from in-
travitreal injection of VEGF in C57BL/6J mice. A similar 
study without prior OCT selection was also performed by 
this laboratory in which SU1498 (50mg/kg) was given via 
oral gavage. In this study, 6 doses of SU1498 (or vehicle) 
were delivered to 10 week LHTag mice (n=5 per group) 
twice weekly for 3 weeks. Mice were enucleated at 16 weeks 
of age, and eyes were formalin-fixed, paraffin-embedded, 
sectioned, and tumor burden was analyzed by H&E staining. 
RESULTS 
  To test the hypothesis that VEGFR-2 expression is 
upregulated during tumorigenesis in the LHTag transgenic 
model of retinoblastoma, we performed immunofluorescence 
analyses. LHTag mice develop multiple, bilateral retinal 
tumors that are typically not visible on histology at 4 weeks 
of age, small at 8 weeks, medium–sized at 10-12 weeks, and 
fill the globe by 16 weeks of age [30]. Eyes from 4, 8, 10-12, 
and 16 week-old transgenic mice and background controls 
were evaluated (n=4 per group). In eyes with medium and 
large tumors, VEGFR-2 expression could be seen in 4 week 
positive mice in the ganglion cell layer and flanking the in-
ner nuclear layer, but overall levels were very low. In con-
trast, VEGFR-2 levels were strongly upregulated in 8, 10-12, 
and 16 week transgenic mice, both in areas of tumor and in 
the retina (Fig. 1). VEGFR-2 immunostaining was most in-
tense in the ganglion cell layer, inner plexiform layer, outer 
plexiform layer, and within the body of tumors. Large tu-
mors (16 week) had VEGFR-2 immunofluorescence 
throughout the tumor (Fig. 1). Immunohistochemical analy-
ses suggest that VEGFR-2 is expressed by Muller glia as 
well as endothelial cells in this tumor. VEGFR-2 staining co-
localizes with molecules associated with Muller glia 
(CRALBP and vimentin) more than with endothelial cells 
(CD105 and lectin, data not shown). 
  In order to confirm the upregulation of VEGFR-2 during 
tumorigenesis, we performed Western blot analyses on reti-
nas and tumors isolated from 4, 8, and 16 week LHTag 
mice and background controls (n=8 retinas per group). 
VEGFR-2 levels were elevated in 8 and 16 week old trans-
genic mice compared with 4 week old mice and negative 
controls (Fig. 2). The activation of VEGFR-2 begins with 
VEGF binding the receptor, leading to its phosphorylation 
[10]. Western blot analysis of pVEGFR-2 levels was   
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Fig. (1). VEGFR-2 immunofluorescence staining in LHTag transgenic 
retinoblastoma. Representative eyes from LHTag mice at 4 (A), 10 (B), 
and 16 (C,D) weeks are shown. VEGFR-2 immunoreactivity is green and 
DAPI counterstaining is blue. GCL, ganglion cell layer; IPL, inner plexi-
form layer; INL, inner nuclear; ONL, Outer nuclear layer. Magnification 
(A) 200 X, (B) 100 X, (C) 200 X. (D) zoomed image from inset of C. 
performed to confirm that VEGFR-2 phosphorylation occurs 
in transgenic retinoblastoma. Levels of pVEGFR-2 were 
elevated in 4- and 16-week-old LHTag retinal and tumor 
extracts compared to controls (Fig. 2). Immunoblots were 
probed for -actin as a loading control (Fig. 2). 
  Since VEGFR-2 is upregulated and phosphorylated in 
transgenic retinoblastoma, we hypothesized that pharmaco-
logically blocking VEGFR-2 would be an effective therapeu-
tic strategy, reducing tumor burden. To test this hypothesis, 
LHTag mice (n=5 per group) were treated with SU1498, a 
drug shown to effectively block retinal leakage in response 
to VEGF intravitreal injections in mice [23]. The same dose 
(50mg/kg) was used in this study, and the drug was delivered 
to 10 week transgenic mice via 6, 10ul periocular injections 
twice weekly for 3 weeks. The vehicle, DMSO, was used as 
a control. Mice were first paired based on tumor size, as de-
termined with spectral OCT imaging. The tumors were 
grouped into small, medium, medium-large, and large sizes 
as described in the methods (Table 1). Side-effects of both 
DMSO and SU1498 included moderately severe orbital fi-
brosis in all animals. Other side effects included corneal 
abrasions and ulceration, conjunctival hyperemia, and 
neovascularization of the cornea in one animal. Abrasions 
and ulcerations were treated with erythromycin ophthalmic 
ointment. No infection or corneal perforations occurred. 
  As shown in Fig. (3A), the tumor burden was decreased 
after treatment with SU1498 compared with DMSO control, 
but not significantly (p=0.29, paired t-test). A 95% confi-
dence interval around the non-significant mean difference of 
DMSO – SU1498 tumor to globe ratio (0.06) ranged from -
0.08 to +0.19. Similarly, analysis of each pair shows no sig-
nificant improvement in SU1498 treated eyes compared to  
 
 
Fig. (2). VEGFR-2 and pVEGFR-2 are upregulated in transgenic 
RB. (A) Western blot analysis was performed in retinal/tumor iso-
lates from LHTag mice and controls at 4, 8, and 16 weeks of age 
(n=8 pooled retinas per group). Actin was probed as a loading con-
trol. One representative blot is shown of 3 replicates. (B) Graphic 
representation of one representative experiment showing quantita-
tive changes in VEGFR-2 and pVEGFR-2 levels (in relative units) 
from Western blot analysis. Animal age (weeks) and tumor status 
(+ for positive or – for negative tumor burden) is indicated on the x-
axis. 
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Fig. (3). VEGFR-2 inhibitor SU1498 did not significantly reduce 
tumor burden. (A) Histologic analysis demonstrates that the average 
tumor burden (tumor/globe ratio) of LHTag right eyes was not 
significantly decreased by six periocular injections of SU1498, 
compared with DMSO control. (B) Scatter plot of tumor burden in 
DMSO-treated versus SU1498-treated eyes. Each point represents 
the tumor burden of one pair, with DMSO tumor burden on the Y-
axis and SU1498 tumor burden on the X-axis. The diagonal line 
indicates equal tumor burden in the SU1498-treated eyes and 
DMSO control. Pairs in which SU1498-treated eyes had smaller 
tumors appear in the upper triangle of the graph. 
controls, although in two pairs the tumor burden was sub-
stantially less in SU1498-treated eyes (Fig. 3B). These nega-
tive data were corroborated by another study in which 
SU1498 (50mg/kg) was delivered to LHTag mice via oral 
gavage instead of periocular injection (n=5 SU1498 and 5 
vehicle controls (data not shown)). 
  Spectral OCT technology has now enabled non-contact, 
in vivo imaging of LHTag retinal tumor response to drug 
therapies. Two paired mice (study number II8 and MM8) 
were imaged once each week during the course of the ex-
periment, and their tumors were followed. Both SU1498 and 
DMSO treated animals showed linear increases in tumor 
volume during the 2 weeks evaluated, with no significant 
differences (Fig. 4). By the third week of the experiment 
(age 13 weeks), the tumor volume was not measured since 
tumor size exceeded the detection boundaries of this system 
(data not shown). The calculated tumor volumes (in cubic 
millimeters) are shown in Table 2. 
DISCUSSION 
  Herein we show that although VEGFR-2 is upregulated 
and phosphorylated in transgenic murine retinoblastoma dur-
ing tumorigenesis, treatment with the VEGFR-2 blocking 
drug SU1498 does not significantly decrease tumor burden at 
the dose studied, even though SU1498 tumor burden was 
substantially less in two animal pairs. To our knowledge, this 
is the first study to (1) pair animals with equivalent ocular 
tumor burden, in a transgenic model, and (2) follow tumor 
burden response to drug therapy in vivo, with OCT technol-
ogy. 
  The dose of SU1498 was carefully selected (a dose with 
known in vivo activity in mice [23]) and was delivered by 
both periocular injection and oral gavage. In contrast, two 
other anti-angiogenic drugs: anecortave acetate and combre-
tastatin A-4, both significantly impacted transgenic retino-
blastoma tumor volume [6,7]. 
  Of VEGF receptors, VEGFR-2 is most important in me-
diating angiogenesis; alone it is sufficient to mediate all of 
the angiogenic responses to VEGF [19,32]. Tumor growth 
has been successfully inhibited by manipulating VEGFR-2 
activity, by using a dominant negative mutant of VEGFR-2 
[15] and antibodies that block VEGF activity [20,21]. Fur-
ther, novel anti-tyrosine kinase drugs specific for VEGF re-
ceptors, including PTK787/ZK 222584, ZD 6474, and   
 
Table 1.  LHTag Mice were Paired into Groups with Equivalent Tumor Burden Prior to Initiating Therapy. The Final Tumor 
Areas (in Pixels, Determined from Histology) After Treatment are Shown 
 
Pair Number  Initial Tumor Size  Final Tumor Area (SU1498)  Final Tumor Area (DMSO) 
1 (II5:LL3)  Very Large  137,509  169,258 
2 (II6: JJ9)  Large  69,321  22,721 
3 (LL1-LL2)  Large  54,585  324,610 
4 (II8:MM8)  Medium  74,099  78,967 
5 (KK1:KK3)  Medium  85,129  67,897 
Average    84,129 132,691 
Standard dev.    31,793 119,737 
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Fig. (4). OCT effectively imaged tumor burden changes in response 
to SU1498 treatment. In vivo imaging was performed on a regis-
tered tumor in one matched pair of LHTag mice. (A) Pictures of 
the tumor in cross-section are shown prior to treatment (time 0, age 
10 weeks), 1 week post-injection number 1 (11 weeks), and 2 
weeks post injection number 1 (12 weeks). (B) Graph of the tumor 
volume determined by OCT segmentation methods. 
SU5416, have shown promise in animal models and phase 
I/II trials for several cancers [16-18,21,33]. However, tumors 
may be able to make several different angiogenic factors as 
they develop; allowing compensation for the inactivation of 
one pro-angiogenic pathway (e.g., tumor bFGF levels in-
creased in breast tumors when VEGF expression was elimi-
nated) [34]. Thus, adding an anti-angiogenic drug with a 
different mechanism (such as endostatin) to VEGFR-2 in-
hibitors may significantly improve efficacy, as shown by 
Abdollahi et al. [35]. 
  Anecortave acetate, an angiostatic cortisene, blocks angi-
ogenesis by inhibiting matrix metalloproteinases and 
urokinase plasminogen activator [36]. Combretastatin A-4 is 
a microtubule-binding agent which targets angiogenic ves-
sels, in part by disrupting vascular endothelial-cadherin sig-
naling [37]. It is tempting to speculate that the mechanisms 
of these drugs are more far-reaching in inhibiting the multi-
faceted angiogenic responses of transgenic retinoblastoma 
tumors. In fact, inhibiting multiple classes of VEGF recep-
tors or all VEGF isoforms may have a greater efficacy 
against transgenic retinoblastoma tumors. Recently, Gille et 
al. [38] showed no significant impact on metastatic mela-
noma tumor burden when just VEGFR-1 or -2 was targeted, 
but a significant reduction in tumor burden was achieved 
when both treatments were combined. 
  In summary, targeting the angiogenic response of retino-
blastoma tumors seems to be a promising therapeutic strat-
egy. However, significant testing of combination strategies 
may be necessary to find the most efficacious therapies. 
ACKNOWLEDGEMENTS 
  We would like to thank Gabe Gaidosh for confocal mi-
croscopy assistance and Magda Celdran for excellent histol-
ogy. We thank Dr. George Hoppe for helpful comments on 
Western blot. This work was supported by NIH RO1 
EY013629, NIH P30-EY014801, and Research to Prevent 
Blindness. 
REFERENCES 
[1]  Tapper D, Langer R, Bellows AR, Folkman J. Angiogenesis capac-
ity as a diagnostic marker for human eye tumors. Surgery 1979; 86: 
36-40. 
[2]  Stitt AW, Simpson DA, Boocock C, Gardiner TA, Murphy GM, 
Archer DB. Expression of vascular endothelial growth factor 
(VEGF) and its receptors is regulated in eyes with intra-ocular tu-
mours. J Pathol 1998; 186: 306-312. 
[3]  Marback EF, Arias VE, Paranhos A, Jr., Soares FA, Murphree AL, 
Erwenne CM. Tumour angiogenesis as a prognostic factor for dis-
ease dissemination in retinoblastoma. Br J Ophthalmol 2003; 87: 
1224-1228. 
[4]  Rossler J, Dietrich T, Pavlakovic H, et al. Higher vessel densities 
in retinoblastoma with local invasive growth and metastasis. Am J 
Pathol 2004; 164: 391-394. 
[5]  Pe'er J, Neufeld M, Baras M, Gnessin H, Itin A, Keshet E. Rubeo-
sis iridis in retinoblastoma. Histologic findings and the possible 
role of vascular endothelial growth factor in its induction. Oph-
thalmology 1997; 104: 1251-1258. 
[6]  Escalona-Benz E, Jockovich M-E, Murray TG, et al. Combretas-
tatin a-4 prodrug in the treatment of a murine model of retinoblas-
toma. Invest Ophthalmol Vis Sci 2005; 46: 8-11. 
[7]  Jockovich ME, Murray TG, Escalona-Benz E, Hernandez E, Feuer 
W. Anecortave acetate as single and adjuvant therapy in the treat-
ment of retinal tumors of LH(beta)T(ag) mice. Invest Ophthalmol 
Vis Sci 2006; 47: 1264-1268. 
Table 2.  Tumor Volume Calculations, in Cubic Millimeters, from Spectral OCT Imaging  
 
Pair Number  Tumor Volume Week 0  Tumor Volume Week 1  Tumor Volume Week 2 
II8 (SU1498)  0.0338  0.0540  0.0697 
MM8 (DMSO)  0.0267  0.0507  0.0712 
..
!()

 
 

  
 !"
#%
/	.01 


2
23
2
24
2
25
2
2


#%
/	.01


..
!()
  
 !"

 
 

#
$
%

&




+
$
%




%
%





5Lack of Effect of SU1498  The Open Ophthalmology Journal, 2008, Volume 2    67 
[8]  Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regula-
tion of angiogenesis via vascular endothelial growth factor recep-
tors. Cancer Res 2000; 60: 203-212. 
[9]  Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduc-
tion. Sci STKE 2001; 2001: re21-. 
[10]  Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its 
receptors. Nat Med 2003; 9: 669-676. 
[11]  Stone J, Itin A, Alon T, et al. Development of retinal vasculature is 
mediated by hypoxia-induced vascular endothelial growth factor 
(VEGF) expression by neuroglia. J Neurosci 1995; 15: 4738-4747. 
[12]  Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M. Es-
sential role of flk-1 (VEGF receptor 2) tyrosine residue 1173 in 
vasculogenesis in mice. Proc Natl Acad Sci USA 2005; 102: 1076-
1081. 
[13]  Witmer AN, Blaauwgeers HG, Weich HA, Alitalo K, Vrensen 
GFJM, Schlingemann RO. Altered expression patterns of VEGF 
receptors in human diabetic retina and in experimental VEGF-
induced retinopathy in monkey. Invest Ophthalmol Vis Sci 2002; 
43: 849-857. 
[14]  Schweigerer L. Antiangiogenesis as a novel therapeutic concept in 
pediatric oncology. J Mol Med 1995; 73: 497-508. 
[15] Millauer  B,  Longhi MP, Plate KH, et al. Dominant-negative inhibi-
tion of flk-1 suppresses the growth of many tumor types in vivo. 
Cancer Res 1996; 56: 1615-1620. 
[16]  Hess-Stumpp H, Haberey M, Doz P, Thierauch K-H. PTK 787/zk 
222584, a tyrosine kinase inhibitor of all known VEGF receptors, 
represses tumor growth with high efficacy. ChemBioChem 2005; 
6: 550-557. 
[17]  Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, 
Tonn JC. Ptk787/zk222584, an inhibitor of vascular endothelial 
growth factor receptor tyrosine kinases, decreases glioma growth 
and vascularization. Neurosurgery 2004; 55: 426-432; discussion 
432. 
[18]  Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, 
Gajewski TF. Phase II study of the flk-1 tyrosine kinase inhibitor 
SU5416 in advanced melanoma. Clin Cancer Res 2004; 10: 4048-
4054. 
[19]  Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting 
the VEGF receptor-2 (flk1/kdr) as an anti-angiogenic therapeutic 
strategy. Cancer Metastasis Rev 1998; 17: 155-161. 
[20]  Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth 
factor receptor (fetal liver kinase 1) monoclonal antibody inhibits 
tumor angiogenesis and growth of several mouse and human tu-
mors. Cancer Res 1999; 59: 5209-5218. 
[21]  Brazelle WD, Shi W, Siemann DW. VEGF-associated tyrosine 
kinase inhibition increases the tumor response to single and frac-
tionated dose radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65: 
836-841. 
[22]  Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor 
growth inhibition. Cancer Res 1996; 56: 3540-3545. 
[23]  Saishin Y, Saishin Y, Takahashi K, et al. Inhibition of protein 
kinase c decreases prostaglandin-induced breakdown of the blood-
retinal barrier. J Cell Physiol 2003; 195: 210-219. 
[24]  Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in trans-
genic mice. Nature 1990; 343: 665-669. 
[25]  O'Brien JM, Marcus DM, Bernards R, et al. A transgenic mouse 
model for trilateral retinoblastoma. Arch Ophthalmol 1990; 108: 
1145-1151. 
[26]  O'Brien JM, Marcus DM, Niffenegger AS, et al. Trilateral retino-
blastoma in transgenic mice. Trans Am Ophthalmol Soc 1989; 87: 
301-322; discussion 322-306. 
[27]  Marcus DM, Lasudry JG, Carpenter JL, et al. Trilateral tumors in 
four different lines of transgenic mice expressing SV40 T-antigen. 
Invest Ophthalmol Vis Sci 1996; 37: 392-396. 
[28]  Albert DM, Griep AE, Lambert PF, Howes KA, Windle JJ, Lasu-
dry JG. Transgenic models of retinoblastoma: What they tell us 
about its cause and treatment. Trans Am Ophthalmol Soc 1994; 92: 
385-400; discussion 400-381. 
[29]  Mills MD, Windle JJ, Albert DM. Retinoblastoma in transgenic 
mice: Models of hereditary retinoblastoma. Surv Ophthalmol 1999; 
43: 508-518. 
[30]  Jockovich M-E, Bajenaru ML, Pina Y, et al. Retinoblastoma tumor 
vessel maturation impacts efficacy of vessel targeting in the LHbe-
taTag mouse model. Invest Ophthalmol Vis Sci 2007; 48: 2476-
2482. 
[31]  Ruggeri M, Wehbe H, Jiao S, et al. In vivo three-dimensional high-
resolution imaging of rodent retina with spectral-domain optical 
coherence tomography. Invest Ophthalmol Vis Sci 2007; 48: 1808-
1814. 
[32]  Gille H, Kowalski J, Li B, et al. Analysis of biological effects and 
signaling properties of FLT-1 (VEGFR-1) and KDR (VEGFR-2). 
A reassessment using novel receptor-specific vascular endothelial 
growth factor mutants. J Biol Chem 2001; 276: 3222-3230. 
[33]  Lee L, Sharma S, Morgan B, et al. Biomarkers for assessment of 
pharmacologic activity for a vascular endothelial growth factor 
(VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): Trans-
lation of biological activity in a mouse melanoma metastasis model 
to phase I studies in patients with advanced colorectal cancer with 
liver metastases. Cancer Chemother Pharmacol 2006; 57: 761-771. 
[34]  Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial 
growth factor is essential for initial but not continued in vivo 
growth of human breast carcinoma cells. Cancer Res 1997; 57: 
3924-3928. 
[35]  Abdollahi A, Lipson KE, Sckell AZ, et al. Combined therapy with 
direct and indirect angiogenesis inhibition results in enhanced 
antiangiogenic and antitumor effects. Cancer Res 2003; 63: 8890-
8898. 
[36]  Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an 
angiostatic steroid on neovascularization in a rat model of retinopa-
thy of prematurity. Invest Ophthalmol Vis Sci 2001; 42: 283-290. 
[37]  Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phos-
phate induces rapid regression of tumor neovessels and growth 
through interference with vascular endothelial-cadherin signaling. J 
Clin Invest 2005; 115: 2992-3006. 
[38]  Gille J, Heidenreich R, Pinter A, et al. Simultaneous blockade of 
vegfr-1 and vegfr-2 activation is necessary to efficiently inhibit ex-
perimental melanoma growth and metastasis formation. Int J Can-
cer 2007; 120: 1899-1908. 
 
 
Received: February 1, 2008  Revised: February 28, 2008  Accepted: March 1, 2008 
 
 
 